Last reviewed · How we verify
Cohort 1 CTAP101 Capsules - 90µg — Competitive Intelligence Brief
phase 2
PTHrP analogue
PTHrP
Osteoporosis
Small molecule
Live · refreshed every 30 min
Target snapshot
Cohort 1 CTAP101 Capsules - 90µg (Cohort 1 CTAP101 Capsules - 90µg) — OPKO Health, Inc.. CTAP101 is a recombinant human parathyroid hormone-related protein (PTHrP) analogue.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cohort 1 CTAP101 Capsules - 90µg TARGET | Cohort 1 CTAP101 Capsules - 90µg | OPKO Health, Inc. | phase 2 | PTHrP analogue | PTHrP |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (PTHrP analogue class)
- OPKO Health, Inc. · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cohort 1 CTAP101 Capsules - 90µg CI watch — RSS
- Cohort 1 CTAP101 Capsules - 90µg CI watch — Atom
- Cohort 1 CTAP101 Capsules - 90µg CI watch — JSON
- Cohort 1 CTAP101 Capsules - 90µg alone — RSS
- Whole PTHrP analogue class — RSS
Cite this brief
Drug Landscape (2026). Cohort 1 CTAP101 Capsules - 90µg — Competitive Intelligence Brief. https://druglandscape.com/ci/cohort-1-ctap101-capsules-90-g. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab